Lyra Therapeutics, Inc.
LYRA · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.52 | 2.75 | 0.24 |
| FCF Yield | -54.70% | -2.13% | -1.68% | -1.93% |
| EV / EBITDA | -2.04 | -49.58 | -69.24 | -88.83 |
| Quality | ||||
| ROIC | -18.34% | -18.02% | -19.74% | -18.36% |
| Gross Margin | -9.29% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 1.23 | 0.89 | 1.03 | 1.03 |
| Growth | ||||
| Revenue 3-Year CAGR | -25.01% | -14.64% | -3.16% | 4.02% |
| Free Cash Flow Growth | 25.24% | 21.71% | 30.60% | 19.34% |
| Safety | ||||
| Net Debt / EBITDA | -0.37 | -0.19 | 0.64 | -1.20 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -306.00 | 0.00 | 0.00 | -5,289.23 |